ClinicalTrials.gg
CompletedNCT06900439Updated Sep 8, 2025

Exploring Glycemic Responses Through Continuous Monitoring in a Healthy Population

An interventional study of Dietary Intervention in Gut Microbiome and Glucose Control, sponsored by Zoe Global Limited. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Zoe Global Limited · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,189
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

PREDICT REFINE is a sub-study of PREDICT 3 with the primary aim of exploring glycemic responses through continuous glucose monitoring in a healthy population. The study will explore glycemic responses to a standardised test meal before and after a personalised dietary programme.

The sub-study will include wearing a Continuous Glucose Monitor for 14 days, collecting information around diet and health, providing a stool sample, and consuming a standardised test meal.

By conducting this study researchers hope to better understand Continuous Glucose Monitoring accuracy and variability in healthy individuals, the impact of diet on glycemic responses over time, and potential mechanisms by which changes in microbiome health may influence glycemic control.

Read the detailed description

PREDICT REFINE is a single-arm mechanistic intervention study designed as a sub-study of PREDICT 3. The primary objective is to explore glycemic responses through continuous glucose monitoring (CGM) in a healthy population, specifically examining responses to a standardized test meal before and after a personalised dietary programme.

Study Population and Recruitment:

The study population consists of individuals who have previously enrolled in the commercial ZOE testing program, consented to participate in the PREDICT 3 study, and provided consent for scientific research at ZOE. Prospective participants will be selected based on predefined inclusion and exclusion criteria by the study management team. Recruitment will be conducted via email, with potential participants receiving a Participant Information Sheet. A minimum of 24 hours will be provided for individuals to consider participation. Those interested will complete an online screening form via a secure survey platform, and eligible participants will be asked to provide informed consent.

Study Design and Procedures:

Following informed consent, participants will undergo the following study tasks in a 14 day timeframe:

  1. Continuous Glucose Monitoring: Participants will wear a CGM device for 14 days to record continuous data on blood glucose responses.
  2. Data Collection: Participants will be required to provide comprehensive information about their diet and health during the study period. This will include completing food logs, a food frequency questionnaire, and a health + lifestyle questionnaire on a mobile app.
  3. Biological Sample Collection: Participants will provide a stool sample, which will be analyzed using metagenomic sequencing.
  4. Consume a Standardized Test Meal: Participants will consume a standardized test meal under controlled conditions.

As participants will be recruited from the PREDICT 3 study, the above tasks would have been completed at baseline, \~4 months prior to the start of the sub study while participating in PREDICT 3. Study consent will allow baseline and endpoint data (collected as part of this sub-study) to be connected.

02

Conditions studied

  • Gut Microbiome
  • Glucose Control

Keywords

  • CGM
  • Continuous Glucose Monitor
  • Glucose
  • Gut Microbiome
  • Healthy Population
  • Glycemic Response
03

In context

Lead sponsor

Zoe Global Limited is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Enrolled in the ZOE product \& purchased a Gut Health Retest at month 4
  • Any sex
  • Minimum 18 years of age
  • (BMI) greater than or equal to 18.5 kg/m2
  • If under care for any chronic medical conditions (including type 2 diabetes), you have confirmed with your treating physician that this sub study is safe for you. This does not apply to conditions listed in the exclusion criteria.
  • Able and willing to comply with the study protocol and provide before your ZOE Gut Health Retest is fulfilled and posted.
  • Live in the United Kingdom

Exclusion criteria

Exclusion Criteria:

  • Cannot safely eat the standardised meals (part of the ZOE product) which contain standard UK ingredients, e.g. due to allergy or recent gastrointestinal surgery
  • Cannot safely use the cgm (per manufacturer's for use including critically ill, pregnant, receiving dialysis, or have an implantable medical device)
  • Are pregnant
  • Have had a heart attack (myocardial infarction), stroke/ (TIA), or major surgery in the last two months
  • Are unable to read and write in English, as the ZOE app is only available in English.
  • Are diagnosed with type 1 diabetes and/or require the use of exogenous insulin or oral hypoglycaemic medications to regulate blood sugar levels
  • Have an active eating disorder (e.g. anorexia nervosa or bulimia nervosa)
  • Have an active gut or digestive system disease (e.g. IBD, Crohn's disease or ulcerative colitis)
  • Are undergoing chemotherapy treatment for cancer
  • Unable to complete study tasks by 31 May 2025
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,189 participants (actual)

Study arms

  • Experimental
    Dietary Intervention

    Dietary intervention using a standardized test meal after which the postprandial glucose response is measured.

    Other: Dietary Intervention

Interventions

  • OtherDietary Intervention

    To carry out a dietary intervention using a standardized test meal where the participant's postprandial glucose to the meal is measured with a continuous glucose monitor and compared to the participant's postprandial glucose from the same standardized test meal 4 months prior.

06

What researchers measure

Primary outcomes

  1. Glycaemic Control

    Measurement of glycaemic control with a continuous glucose monitor (CGM).

    Time frame: Baseline and Month 4

Secondary outcomes

  1. Gut Microbiome Composition

    The measurement of relative abundance of microbiome species, derived from metagenomic analysis of stool samples.

    Time frame: Baseline and Month 4

  2. Gut Microbiome Diversity

    The measurement of diversity metrics (e.g. richness, evenness, ranking of species associated with diet and health) derived from metagenomic analysis of stool samples.

    Time frame: Baseline and Month 4

Other outcomes

  1. Dietary Intake

    The measurement of habitual and acute dietary intake through a food frequency questionnaire and food logs.

    Time frame: Baseline and Month 4

07

Study locations

1 site
  • ZOE Limited
    London, SE17RW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in May 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2025
First posted
Mar 28, 2025
StartActual
Mar 21, 2025
Primary completionActual
May 31, 2025
CompletionActual
May 31, 2025
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06900439
Lead sponsor
Zoe Global Limited
Responsible party
Sponsor
First posted
Mar 28, 2025
Start date
Mar 21, 2025
Primary completion
May 31, 2025
Completion
May 31, 2025
Last update
Sep 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion